

Drug Monograph

Drug/Drug Class: **Aristada Initio™ (aripiprazole lauroxil) extended-release injectable suspension/Atypical Antipsychotic**

Prepared for: MO HealthNet
Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Aristada Initio™ is an extended release, intramuscular injection suspension available in a 675mg single dose pre-filled syringe.	
Indications:	Aristada Initio™, in combination with oral aripiprazole, is indicated for the initiation of Aristada® when used for the treatment of schizophrenia in adults.	
Costs:	\$1,869.55 per 5-ml pre-filled syringe of Aristada Initio® 675mg. Maximum Allowable Cost	
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).	
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE	<input checked="" type="checkbox"/> Preferred
	<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> No PA Required

Prepared By: Jennifer Anderson PharmD
Date: October 15, 2018